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ABSTRACT: Developing countries have significantly con-
tributed to the elucidation of the genetic basis of both
common and rare disorders, providing an invaluable
resource of cases due to large family sizes, consanguinity,
and potential founder effects. Moreover, the recognized
depth of genomic variation in indigenous African
populations, reflecting the ancient origins of humanity
on the African continent, and the effect of selection
pressures on the genome, will be valuable in under-
standing the range of both pathological and nonpatholo-
gical variations. The involvement of these populations in
accurately documenting the extant genetic heterogeneity
is more than essential. Developing nations are regarded
as key contributors to the Human Variome Project
(HVP; http://www.humanvariomeproject.org), a major
effort to systematically collect mutations that contribute
to or cause human disease and create a cyber infra-
structure to tie databases together. However, biomedical
research has not been the primary focus in these
countries even though such activities are likely to
produce economic and health benefits for all. Here, we
propose several recommendations and guidelines to
facilitate participation of developing countries in genetic
variation data documentation, ensuring an accurate and
comprehensive worldwide data collection. We also
summarize a few well-coordinated genetic data collection
initiatives that would serve as paradigms for similar
projects.
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Introduction
The recent elucidation of the genome sequence of several
individuals, such as Causacians (Jim Watson [Wheeler et al., 2008]
and Craig Venter [Levy et al., 2007]), West African [Bentley et al.,
2008], and Han Chinese [Wang et al., 2008], suggests that a large
number of single nucleotide polymorphisms (SNPs) and other
sequence variation exists in the human population. Estimates from
African genetic diversity and the Pan Asian SNP initiative suggest
that approximately 80–90% of human genomic variation resides in
the world’s developing countries [Hinds et al., 2005]. It is therefore
obvious that there is a huge need to comprehensively document
the extant genetic variation in various ethnic groups and
populations around the globe to ensure maximal data coverage.
Since 2002, there have been several initiatives to thoroughly
document the genetic heterogeneity in various populations
worldwide in National/Ethnic Mutation databases (NEMDBs), a
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Greece. E-mail: gpatrinos@upatras.grlarge number of which reside in developing countries. Despite the
fact that data content is rather homogeneous, facilitated by the
existence of an off-the-shelf database management system [van
Baal et al., 2010], these databases have been developed without
appropriate guidelines and recommendations to ensure not only a
thorough description of common and rare genetic diseases in
these populations but also maximal visibility and usefulness of
these resources in the respective countries while maintaining the
individual local ethical and cultural values in them. Furthermore,
developing countries are often a valuable resource of clinical
samples that derive from consanguineous families with very
unusual phenotypes. These genotype and phenotype data are
worth being recorded in NEMDBs not only to make them readily
available to interested parties but also to develop and implement
genetic epidemiological approaches for estimating the relative
frequency of rare autosomal recessive disorders and an estimate of
their prevalence in these populations.
Here, we propose a number of guidelines and recommendations
that would assist in genetic variation data capture in developing
countries to ensure a comprehensive worldwide data collection,
one of the aims and goals of the Human Variome Project (HVP)
[Cotton et al., 2007; Kaput et al., 2009] (www.humanvariome
project.org). These guidelines are largely the result of discussions
among the participants of the developing countries working group
during the International HVP Planning and Implementation
meetings in May 2008 and 2010, respectively, coming from a wide
range of developed and developing countries and extended, based
on ongoing data documentation efforts in these countries.
Background
Any formal attempt to identify the extent of genetic variation
must include geographical regions that have not been included in
previous haplotype mapping projects, for example, the HapMap
project, particularly because the latter project included racial and
not population groups. Although the Population Reference
Sample (POPRES) will address some of these missing populations
[Nelson et al., 2008], this effort is again designed as a mapping
project that is not expected to focus on functional polymorphisms
or mutations. Also, the Arab region has long played a key role in
discovering new genes and it is really awkward why this region has
not been so actively involved in today’s genomics research and
genome-wide association studies.
Hence, one of the main activities of the HVP is the analysis and
subsequent inclusion of genetic variation data from clinical samples
originating from diverse populations or ethnic groups [Cotton et al.,
2009; Kaput et al., 2009]. The distinct advantage of some ethnic
populations is the opportunity to study genetic diseases due to: (1)
large family size, (2) consanguinity, and (3) potential founder effects
[Saadallah and Rashed, 2007]. In fact, several disorders have been
described for the first time in certain populations residing in
developing countries, for example, Sanjad-Sakatti syndrome, Teebi-
Shaltoot syndrome, Teebi Hypertelorism, and others. Based on the
abovementioned advantages, developing nations are regarded as
major contributors to the HVP even though biomedical research has
not been the focus of these countries, despite such activities being
likely to produce economic and health benefits for all [Kaput et al.,
2009; Singer and Daar, 2001].
The NEMDBs are one of the main components of the HVP that
could accommodate the extant genetic heterogeneity in the
developing countries and, for that matter, all countries. In
particular, the NEMDBs are mutation depositories needing
continuous updating, recording extensive information over the
described genetic heterogeneity of an ethnic group or population
(reviewed in [Patrinos, 2006]). NEMDBs can help optimize
national molecular diagnostic services, by stratifying the corre-
sponding mutation spectra in various inherited diseases, and assist
in interpreting diagnostic test results in countries with hetero-
geneous populations, particularly in minority ethnic groups.
NEMDBs can also contribute toward the elucidation of the origin
and migration of populations, acting as platforms for comparative
genomic studies that can reciprocally provide insights into, for
example, the demographic history of human populations, patterns
of their migration and admixture, gene/mutation flow, etc.
[Patrinos, 2006]. Such comprehensive databases would include
information on genotype and reasonable phenotype, in a level of
detail that should be agreed by the community, which would also
enable those interested in these diseases to investigate the possible
influence of geographical environment or genetic modifiers on
expression of the disease/phenotype. Examples include the
genetics of obesity, hypertension, or type II diabetes. Relevant
genotype/phenotype collection projects, such as GEN2PHEN
(http://www.gen2phen.org) or P3G (http://www.p3g.org) could
serve as models to establish the necessary requirements for the
depth of the recorded genotype and phenotype information.
Recommendations
The recommendations and guidelines that follow (summarized
in Box 1) are intended to facilitate genetic variation data capture
in developing countries, either by suggesting specific measures
aiming to enhance awareness among clinicians, bioscientists, and
the general public about the range of commonest genetic disorders
suffered by certain populations and/or ethnic groups, or by
sharing the experience from ongoing projects to document genetic
heterogeneity in different countries.
Box 1. Guidelines and recommendations for data capture in
developing countries
1. Develop procedures to include clinicians and researchers in developing
nations, mostly by creating networks among those of common interest.
2. Create international networks from closely related populations to enhance
communication, interaction, and initiate research networks between them.
3. Foster communication, interaction, and research networks between
developing and developed countries.
4. Ensure that the database management systems that are being used or
developed can be utilized by those in a limited resource environment.
5. Provide support to developing countries to build capacity and to fully
participate in the collection, analysis, and sharing of genetic variation
information.
6. Develop a framework to facilitate interactions between the coordinating center
and national, regional, and international agencies.
7. Ensure that all ethical, legal, religious, and social issues are thoroughly
considered when NEMDBs and/or data capture projects are launched in
developing countries.
1. Develop Procedures to Include Clinicians and
Researchers in Developing Nations, Mostly by Creating
Networks Among Those of Common Interest
This would be particularly important for clinicians/researchers
working in underresourced institutes and research environments.
Where construction of a NEMDB is decided, selected representa-
tives from participating laboratories, mainly established scientists
and principal investigators involved in human genetics, should
take the lead in this effort. These individuals would form the
advisory committee of the NEMDB with one of them assigned as
HUMAN MUTATION, Vol. 32, No. 1, 2–9, 2011 3national coordinator with a defined (e.g., yearly) term. These
members will then assign eligible members from their groups
that would serve as data curators responsible for data entry/
modification.
Such efforts would flourish if placed under the umbrella of
specific scientific initiatives or consortia (see also below), such as
the Human Genome Variation Society (HGVS; www.hgvs.org), a
Society that generates recommendations and guidelines toward
human genome variation capture, the HVP, and ORPHANET
(http://www.orpha.net), a database of information on rare diseases
and orphan drugs, with presence in 37 mostly European and Arab
countries, that aims to contribute to the improvement of the
diagnosis, care, and treatment of patients with rare diseases. This
approach is already adopted in the Israeli and Greek genetics
communities, mostly to share genetic laboratory information, but
also to accelerate the data collection process. Partnering with local
human genetic societies is also liable to have the same result.
Moreover, to increase awareness among interested parties, the
resulting NEMDBs should be made known to their potential users
using various communication channels. These do not necessarily
include international scientific journals to which local institutes in
these countries might not have access, but local scientific journals,
news bulletins, scientific events (symposia, workshops), one-to-
one communication, and so on. Such an approach was followed
by the Israeli NEMDB, by producing a review article in the Israeli
Medical Association Journal, a leading peer-reviewed scientific
medical journal in Israel [Zlotogora et al., 2009].
2. Create International Networks from Closely Related
Populations to Enhance Communication, Interaction, and
Initiate Research Networks Between Them
In this case, it would be mutually beneficial for closely related
countries such as in Latin America, the Middle East, or regions in
Africa, to initiate new or strengthen existing collaborative ties
toward comprehensive genetic variation data capture. Similarly,
specific resources would be committed in different countries so
that there will be no redundancy in their research efforts. In this
regard, the Catalogue for Transmission Genetics in Arabs (CTGA)
([Tadmouri et al., 2006]; see also below) initiated from the Centre
for Arab Genomic Studies (http://www.cags.org.ae) in Dubai,
United Arab Emirates, is a pilot project to document genetic
disorders in Arab populations from the published literature. The
current version of CTGA database contains nearly 760 full-text
records for nearly 1,290 Mendelian disorders and related genes,
including extensive data from the United Arab Emirates, Bahrain,
Oman, and Qatar.
3. Foster Communication, Interaction, and Research
Networks Between Developing and Developed Countries
This would be particularly beneficial in both data collection
from the literature or generation of new genetic variation data and
would include:
a. Education of healthcare providers, the public, and government
officials from researchers and health care providers from
developed countries, regarding data collection, data generation
and interpretation, and so on. To this end, the Pan-Arab
Human Genetics conferences, with international participation
from developed countries, could very well be an example of
such interactions. The African Society for Human Genetics is
also spearheading efforts to create a database of genetic
variation in indigenous African populations (Raj Ramesar;
personal communication; Al Aama and coworkers, submitted).
b. Assistance in data handling and storage in large databases and
servers in developed countries, particularly where massive
storage units (e.g., GRIDs) are needed to accommodate large
datasets. Such possibilities are currently offered by LSDB and
NEMDB software developers (LOVD [Fokkema et al., 2005]
and ETHNOS [van Baal et al., 2010], respectively) in The
Netherlands and Greece, respectively, to either download for
use or to store in their local servers, data from interested parties
and curators that do not have either the knowledge or the
resources needed, although ultimately the aim would be to
provide the infrastructure locally.
c. Consultancy in the design and coordination of large-scale
genome projects (see also below) if such need arises, including
patients recruitment, experimental design, software/database
development (see also Point 5).
d. Outsourcing of high-throughput experiments, such as micro-
array or next-generation sequencing experiments, to labora-
tories in the developed countries, where such infrastructure
and expertise is more likely to be available, but also provide
expert external training to those countries where the facilities
are available but outstrip the local expertise.
e. To work interactively, leading from all of the above, to train
postgraduate students and other researchers toward capacity
development in developing countries.
4. Ensure That the Database Management Systems That
Are Being Used or Developed Can Be Utilized by Those in
a Limited Resource Environment
Today, LSDBs and NEMDBs, which capture the core informa-
tion in any one of these domains of information, are developed by
experts and curated with invaluable skill and experience. Often,
developing countries suffer from a limited resource research
environment; hence, this reality should be carefully considered
when database management systems are developed for this
purpose.
Therefore, the database management system should be designed
and built such that the resulting database would:
a. Record the specific variants of inherited disorders found in a
population or ethnic group in a comprehensive and user-
friendly manner, that is, by providing consistent and simplified
information accompanied by numerous links to other databases
and related resources [Patrinos, 2006].
b. Provide the end user with an interface for easy data query and
retrieval of information pertaining to the mutation spectrum of
each disorder together with the corresponding mutation
frequencies and references.
c. Allow permanent data storage and secure data entry and
modification. In this case, software pipelines should also allow
automated genotype data transfer between the clinic and/or
laboratory to the database, and ideally from the genotyping
equipment (sequencer, scanner, etc.) directly to the database.
d. Operate under strict quality assurance guidelines, such as
intellectual property rights, the professional code of ethics
(http://ihealthcoalition.org/ethics/ehcode.html), or specific
ethical guidelines [Povey et al., 2010], laws on computing
and liberties (e.g., www.ama-assn.org/ama/pub/category/1905.html),
electronic data protection, specific guidelines, and any law or
regulation applicable in addition to the local ethical issues that
may be specific to a given country.
4 HUMAN MUTATION, Vol. 32, No. 1, 2–9, 2011Such databases should be able to operate remotely, should the
required support not be available locally (see also Point 3).
5. Provide Support to Developing Countries to Build
Capacity and to Fully Participate in the Collection,
Analysis, and Sharing of Genetic Variation Information
Comprehensive genetic variation data capture usually entails
highly specialized researchers or diagnostic laboratory staff and
state-of-the-art infrastructure, particularly where generation of
new genomic data comes to play. Developing countries usually
suffer from brain drain and lack of highly sophisticated equipment
to perform cutting-edge research. To this end, developed countries
have the obligation to alleviate this burden and to assist
developing nations by every means possible [Kaput et al., 2009].
It should be noted that developing countries have a valuable
resource of clinical samples, often with very unusual phenotypes,
particularly when consanguineous families are involved because in
this case, the elucidation of the genetic basis of the underlying
phenotype becomes much easier. Developing countries should
therefore:
a. Educate healthcare providers and government officials to
demonstrate the need to initiate documentation of the genetic
variation in their countries and to underline the benefits of
cooperation in biomedical research [Bhan et al., 2007].
b. Increase awareness in the general population about the need to
comprehensively record the underlying genetic heterogeneity in
their country and informing them objectively about the benefits
and risks of such projects.
c. Ascertain all parties involved that the research outcome will
not be misused. Certain populations or ethnic groups in
developing countries usually mistrust research involving genetic
analyses or fear that results can stigmatize them or worse
(http://www.eubios.info/ASIAE/BIAE201.htm). For example,
Malay-Muslims, Chinese, and Indians in Singapore expressed
anxiety about breach of confidentiality, the misuse of their
DNA for cloning, and possibilities of being diagnosed with
disease [Wong et al., 2004]. Community-based research
collaborations may provide fora for addressing cultural and
ethical concerns of biomedical research [Povey et al., 2010].
Analyzing the extent of human genome variation creates an
ideal opportunity for the developed and the developing nations
of the world to forge meaningful partnerships and to work
together in an unprecedented way, initially to identify variation
causing disease, and then to simplify mutation detection in
specific ethnic groups, and then to understand how genetic
variation contributes to human phenotypic diversity. By
ensuring that all nations and ethnic groups have an equal
and fair opportunity to share data and technology, evidence-
based information will be provided such that all populations can
benefit from a global society health network.
d. Emphasize in every stage of the collaborative project that
external input is needed from the design and coordination of
NEMDB development and curation to database hosting and
technical support, patient recruitment, and experimental
design to performing high-throughput experiments in the case
of large-scale genome projects (see also Point 3). To this end,
funding agencies (e.g., UKIERI; UK-India Education and
Research Initiative) could assist by funding innovative projects
so that developing countries become independent and self-
sustained.
e. Develop partnerships for the equitable sharing of knowledge
and technology between developed and developing countries.
These partnerships should be ideally formed under the umbrella
of international organizations, such as the HGVS or the Human
Genome Organization (HUGO; http://www.hugo-international.
org) that would also organize interinstitutional specialized
educational programmes and workshops. The biennial mutation
detection workshop would be a paradigm for this initiative and
may sometimes be held in developing countries.
6. Develop a Framework to Facilitate Interactions
Between the Coordinating Center and National, Regional,
and International Agencies
Researchers and their academic institutions that participate in
national data collection projects and/or NEMDBs development
should jointly develop infrastructures that would ensure smooth
communication between them and national and international
agencies. These include: (1) national governments and their
Departments of Health, Science and Technology, Development,
Education and so on, local human genetic societies; (2) regional
organizations, such as the NEPAD (New Programme for Africa’s
Development); and (3) international organizations, such as the
European Commission (EC), United Nations (UN), United
Nations Children’s Fund (UNICEF), World’s Health Organization
(WHO), Organization for Economic Cooperation and Develop-
ment (OECD), etc.
This, in turn, would: (1) create new collaboration ties with
neighboring countries interested in initiating similar projects, (2)
increase the chances of receiving funding for these activities (see
also below), and (3) increase visibility of the progress to the
international scientific community.
7. Ensure That All Ethical, Legal, Religious, and Social
Issues Are Thoroughly Considered when NEMDBs and/or
Data Capture Projects Are Launched in Developing
Countries
The goal of establishing LSDBs and NEMDBs in developing
countries is the sharing of genetic variation information for the
benefit of the respective populations. This includes the protection
of privacy, which in this context is the right of the individual and
members of their family to be protected against intrusion into
their personal information and further intrusions ensuing from
access to this, by publication of information. Of course, there is no
such issue when summary level data are reported for a population,
as it is the case in some NEMDBs. Therefore, there should be a
balance between the public’s interest in the value of the shared
information and its interest in the strict protection of privacy. This
balance would be viewed differently in different cultures and
ethnicities [Al-Aqeel, 2007].
For many of these NEMDBs, it seems reasonable that an
independent group of qualified scientists oversees these resources
and related activities not only at their initiation but on an ongoing
basis. Where needed, the main purpose of the particular NEMDB
should be clarified, recognizing that this may change with time.
This will allow evaluation of the exact requirements for data
deposition in the NEMDBs, and whether compliance with the
remaining guidelines will be possible with the database content
freely available to the public or partly restricted to registered
persons, namely curators, physicians, and so on. This measure was
implemented in the Israeli NEMDB, where not all information is
HUMAN MUTATION, Vol. 32, No. 1, 2–9, 2011 5made publicly available [Zlogotora et al., 2007], because access to
specific cases is password-protected [Zlotogora et al., 2009].
A similar measure would entail anonymizing genetic data, either
by permanently removing or coding the personal identifiers
[Povey et al., 2010]. Of interest, the newest version of the LOVD
software [Fokkema et al., 2005] has the option to store data that
are not public but that can be queried. The result of a query
hitting nonpublic data is a notification that there is such
information in the database but that the curator needs to be
contacted to get more information.
The depth of the ethnic and geographic origin data should be
determined in advance, particularly in the case of small
villages where carriers of rare variants could be identified even
if personal information were not provided. In this case, data
donors should be well informed and provided with an
explanation as to why their data documentation is useful and
how their privacy is secured. These individuals should consent to
the inclusion of their genetic information in the database and
reserve the right to withdraw their data from the database
whenever they desire. This is particularly important for persons
unable to consent because of disability or young age. Standar-
dized consent forms need to be translated to different local
languages and/or dialects.
Finally, these databases would also benefit from some
independent/external ethical review, perhaps from an interna-
tional group (HGVS or HVP) who could advise them
accordingly.
Nation-Wide Genomic Projects that Would
Serve as Paradigm for Genetic Variation Data
Collection
By definition, a nation-wide genomic project is a national
multicentre initiative to determine the underlying genetic
heterogeneity of a population with the goal to ascertain the
genetic variation leading to common or rare inherited diseases.
Such initiatives consist of three parts: (1) documenting the
genetic heterogeneity that has already been reported in the
published literature, (2) generating new genetic data by screening
a large proportion of the population using high throughput
genotyping approaches, and (3) accumulating data causing
inherited disease from hospitals, laboratories, and other
healthcare facilities. In every case, except perhaps (3), a large
national genetic database/portal is being developed to accom-
modate the sheer amount of data gathered. To date, there are few
nation-wide genomic projects in various developing countries
that are currently in progress. These projects (summarized in
Table 1) implement some of the guidelines described previously.
Also, there are several other NEMDB projects, all of which
more or less follow these guidelines, that have already been
reviewed [Patrinos, 2006; van Baal et al., 2007] and will,
therefore, not be further discussed because they lie outside the
scope of the present article.
The Estonian Genome Project (EGP; http://www.geenivara
mu.ee/index.php?lang5eng) is a research venture of the
University of Tartu initiated in 2001 [Metspalu, 2002] and aims
to create a database of health, genealogical, and genetic data
representing approximately 10% of Estonia’s population. The
database will make it possible for researchers both in Estonia and
outside to look for links between genes, environmental factors,
and common diseases (such as cancer, diabetes, depression,
cardiovascular diseases, etc.). Currently, EGP gene bank contains
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to 100,000 within the next 3 or 4 years.
The Indian Genome Variation database (IGVdb; http://www.
igvdb.res.in) is a consortium activity established in 2003 to
document the inherent genetic variability of the Indian sub-
populations as a first step toward identifying genetic biomarkers
to understand susceptibility for any genetic disease and popula-
tion migration, pharmacogenomic markers to understand variable
drug response. The Indian Genome Variation (IGV) consortium
aims to provide data on validated SNPs and repeats, both novel
and reported, along with gene duplications, in over 1,000 genes
(selected on the basis of their relevance as functional and positional
candidates in many common diseases including genes relevant to
pharmacogenomics), in 15,000 individuals drawn from Indian
subpopulations [Indian Genome Variation Consortium, 2005].
Kuwait established within the Faculty of Medicine, Department
of Pathology a Molecular Genetics Diagnostic Service Division
(http://www.al-mulla.org), integrated within a research laboratory,
which is focused on delivering state-of-the-art diagnostic
service for the Kuwaiti population. These services, which focus
on autozygosity mapping in families with consanguineous
marriages, provide the research laboratory with a unique opportu-
nity to identify novel genes in autosomal recessive disorders.
Moreover, various unique cases suffering from cancer are currently
being analyzed using the Affymetrix Array 6.0 microarray
technology to identify copy number changes and homozygosity
stretches. The data generated from these studies are deposited in
CAGS database (see above), and LOVD, whereas the Kuwaiti
NEMDB has been recently established databases to encourage
data storage for genetic diseases in different subpopulations
in Kuwait.
The United Kingdom has developed a central database to collect
all UK genome variation data, and their effects, from participating
diagnostic laboratories. The diagnostic mutation database
(DMuDB; http://ngrl.org.uk/Manchester/dmudb.html) provides
a route for sharing mutation data within and between diagnostic
laboratories in the United Kingdom to support genetic testing
services for patients. Currently DMuDB has over 4,884 records for
33 genes, namely Breast Cancer (BRCA1, BRCA2), Lowe
Syndrome (OCRL), Sotos Syndrome (NSD1), HNPCC (MLH1,
MSH2), cystic fibrosis (CFTR), X-linked retinitis pigmentosa
(XLRP), neurofibromatosis, Types I and II (NF1, NF2), Alstrom
Syndrome (ALMS1), CADASIL (NOTCH3), familial adenomatous
polyposis (FAP), and muscular dystrophy (DMD), containing over
10,985 individual variants.
The Hellenic Genome Variation database aims to document the
genetic heterogeneity in the Hellenic population. The first version
of the Hellenic NEMDB was created in 2004 [Patrinos et al.,
2005]. In 2007, research institutes involved in hemoglobinopathies
research initiated a pilot multicenter project to determine the
mutation spectrum of the thalassemia syndromes in various
geographical regions in the country with the goal to document the
findings in the Hellenic NEMDB. These data showed that
although Greece is a rather homogeneous country, there are big
qualitative (type of mutations) and quantitative (allelic frequen-
cies) differences in various parts of the country, namely,
central Greece [Samara et al., 2007] and South-Western Greece
[Papachatzopoulou et al., 2010]. These data compared to findings
from North-Western Greece [Georgiou et al., 2003] and the
rest of the country [Patrinos et al., 2005] reveal valuable
information for region-specific population carrier screening
and for efficient provision of prenatal diagnosis of b-thalassemia
in Greece.
Finally, there are four international consortia with activities
related to the documentation of causative mutations and allelic
frequencies in developing countries:
a. The International Society for Gastrointestinal Hereditary
Tumours (InSiGHT; http://www.insight-group.org) is an inter-
national multidisciplinary, scientific organization with a mission
‘‘... to improve the quality of care of patients and their families
with any condition resulting in hereditary gastrointestinal
tumours.’’ The InSiGHTconsortium maintains a LOVD-based
database for genetic variations for the EPCAM, MLH1, MLH3,
MSH2, MSH6, MUTYH, PMS1, and PMS2 genes leading to
gastrointestinal tumors and encourages the establishment of
national repositories for patients suffering from gastrointestinal
tumors, particularly in developing countries.
b. The International Thalassemia Network (ITHANET; http://
www.ithanet.eu) is a European Commission-funded project that
comprises a network of all major European research institutions
active in the field of molecular and clinical research of
thalassemia and related hemoglobinopathies [Lederer et al.,
2009]. Among its activities, ITHANET hosts a database
(ITHANETbase) that includes mutation frequencies in various
populations at-risk for thalassemia, particularly from developing
countries. In many instances though, this repository is largely
redundant to HbVar database of hemoglobin variants and
thalassemia mutations (http://globin/bx.psu.edu/hbvar) [Patrinos
et al., 2004].
c. The MEDGENET project (http://medgenet.tredueuno.it) is a
European Consortium, funded by the European Commission,
aiming to expand the human expertise in clinical genetics in
Mediterranean Partner Countries (MPC) through the transfer
of knowledge and technology between the two rims of the
Mediterranean that share a common burden of genetic diseases.
Among the actions foreseen by MEDGENET is the building of
Medical Genetics databases for the various partner countries.
Several NEMDBs are built from scratch, such as the Tunisian
and Egyptian NEMDBs or expanded from the existing
NEMDBs, such as the Israeli [Zlotogora et al., 2007], Cypriot
[Kleanthous et al., 2006], and Lebanese NEMDBs [Me ´garbane ´
et al., 2006], using the ETHNOS database management system
for NEMDB development and curation [van Baal et al., 2010].
d. The Pharmacogenomics for Every Nation Initiative (PGENI;
www.pgeni.org) that aims to determine the frequencies of the
commonest pharmacogenomic markers in various populations,
particularly from developing countries worldwide.
Finally, there are a few nation-wide DNA biobanks, such as the
National Laboratory for the Genetics of Israeli Populations,
representing a national repository for human cell lines and DNA
from the unique and large ethnic variation of the Israeli
populations (Tel Aviv University; available at http://www.tau.a-
c.il/medicine/NLGIP) or the Biomaterial Banking Medical
Research Initative (BBMRI) in Malta, which of course lie
at the borderline of the nation-wide genomic projects described
above.
Funding and Incentives
There are currently two main obstacles that hinder further
efforts to expand the NEMDB field, namely, funding and
providing incentives to data submitters.
Funding for collecting genetic variation data has traditionally
been difficult due to the extreme fragmentation of the field
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efforts to receive funding for genetic variation data capture are
more likely to flourish if treated as concerted efforts. GEN2PHEN
(http://www.gen2phen.org) represents such initiative that have
already received funding from the EC and aims to unify human
and model organism genetic variation databases toward increas-
ingly holistic views into genotype-to-phenotype data, and to link
this system into other biomedical knowledge sources via genome
browser functionality. Linking population and ethnic-specific
information into LSDBs and diagnostic databases, creating
NEMDBs and developing genomic databases, similar to the
Indian Genome Variation database are key activities for the main
GEN2PHEN work packages. Obviously, other strategically minded
funding agencies (e.g., NIH), charities, and foundations would
also launch similar calls. Recently the Australian Node of the HVP
has been funded to pilot software for data flow from hospitals/
clinics via country specific databases to LSDBs and NCBI/EBI/
UCSC browsers (unpublished). Involving universal organizations
such as the WHO and UNESCO in the fund-raising project will
clearly have a strong impact.
On the other hand, the development of comprehensive analyses
of human genetic variation often reaches a barrier in the form of
the reward system for clinicians and academic researchers. First of
all, database entries could be made a mandatory quality control
standard for clinical laboratories and clinicians. Notably, accord-
ing to a new initiative of the Israeli government, genetic
laboratories are mandated to report the details of the tests they
are performing in the Israeli NEMDB in order to obtain
accreditation from the Israeli Ministry of Health [van Baal et al.,
2010].
For researchers, a publication or Web-based system establishing
microattribution and community annotation of mutations and
cited data will enable measurable contributions to the scientific
knowledge base [Anonymous, 2008; Hoffman, 2008]. Similarly,
database journals would also serve this task by providing a forum
for publishing gene variation data that would be eventually
deposited in the PubMed literature database. One such journal,
the open access Human Genomics and Proteomics (http://
www.sage-hindawi.com/journals/hgp), which is affiliated with
FINDbase (http://www.findbase.org) [van Baal et al., 2007], will
focus on studies characterizing causative mutation and/or
biomarker frequency spectra. Accepted contributions including
datasets will be linked in FINDbase and deposited in PubMed
[Patrinos and Petricoin, 2009]. Also, the journal Human Genetics
has been accepting mutation data and this is linked to HGMD
(http://www.hgmd.org).
Journals, tenure, and promotion committees, and funding
agencies would be encouraged to cite these contributions to and
citations of LSDB and international national databases [Patrinos
and Brookes, 2005]. The rapid progress in genetic research has led
to a declining interest of scientific clinical genetic journals in case
reports with single or few novel mutations. This may deter
clinicians from reporting these new mutations, which collectively
become important, unless another venue becomes visible.
Concluding Remarks
As stated above, documenting population/ethnic-specific data
in developing countries are among the primary objectives of the
HVP that appreciates the genomic sovereignty/equality for all
countries to be involved and acknowledges the value of ‘‘human
capital’’ within all populations. Real and tangible benefits of the
HVP to improve health will be generated for participating
populations. Hence, the voluntary participation of the greatest
number of countries would ensure a more general applicability,
and it is hoped that many countries will eventually decide to
participate.
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